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MAPK-Activated Protein Kinase 2 Contributes to Clostridium difficile-
Associated Inflammation
Linda D. Bobo,b Rana E. El Feghaly,a Yee-Shiuan Chen,a Erik R. Dubberke,b Zhuolin Han,b Alexandra H. Baker,a Jinmei Li,a
Carey-Ann D. Burnham,c David B. Haslama,d
Departments of Pediatrics,a Medicine,b Pathology and Immunology,c and Molecular Microbiology,d Washington University School of Medicine, St. Louis, Missouri, USA
Clostridium difficile infection (CDI) results in toxin-induced epithelial injury and marked intestinal inflammation. Fecal mark-
ers of intestinal inflammation correlate with CDI disease severity, but regulation of the inflammatory response is poorly under-
stood. Previous studies demonstrated that C. difficile toxin TcdA activates p38 kinase in tissue culture cells and mouse ilium,
resulting in interleukin-8 (IL-8) release. Here, we investigated the role of phosphorylated mitogen-activated protein kinase
(MAPK)-activated protein kinase (MK2 kinase, pMK2), a key mediator of p38-dependent inflammation, in CDI. Exposure of
cultured intestinal epithelial cells to the C. difficile toxins TcdA and TcdB resulted in p38-dependent MK2 activation. Toxin-
induced IL-8 and GRO release requiredMK2 activity. We found that p38 andMK2 are activated in response to other actin-dis-
rupting agents, suggesting that toxin-induced cytoskeleton disruption is the trigger for kinase-dependent cytokine response.
Phosphorylated MK2 was detected in the intestines of C. difficile-infected hamsters and mice, demonstrating for the first time
that the pathway is activated in infected animals. Furthermore, we found that elevated pMK2 correlated with the presence of
toxigenic C. difficile among 100 patient stool samples submitted for C. difficile testing. In conclusion, we find that MK2 kinase is
activated by TcdA and TcdB and regulates the expression of proinflammatory cytokines. Activation of p38-MK2 in infected ani-
mals and humans suggests that this pathway is a key driver of intestinal inflammation in patients with CDI.
Clostridium difficile is among the most common hospital-asso-ciated infections, causing gastrointestinal disease which
ranges from mild diarrhea to toxic megacolon, sepsis, and death;
its incidence and case fatality rate are increasing (1–5). The prin-
cipal C. difficile virulence factors are a pair of closely related large
toxins known as TcdA (toxin A) and TcdB (toxin B). These se-
creted toxins bind to host cell receptors, are internalized, and then
are transported into the cytoplasm, where they express their en-
zymatic activity. Specifically, both toxins are glucosyltransferases
that target Rho GTPases (RhoA, Rac1, and Cdc42) (6). Glucosy-
lation inactivates the GTPases, thereby disrupting signaling cas-
cades, arresting cell cycle progression, and damaging cytoskeletal
integrity (6). Immediate effects of cellular intoxication are in-
creased fluid and electrolyte secretion from enterocytes and in-
creased permeability of the intestinal mucosa. Within a few hours
of toxin exposure, enterocytes become rounded and inflamma-
tion ensues (7, 8). Colonic injury in CDI is characterized by
marked neutrophilic infiltration, which likely contributes to the
local and systemic manifestations of CDI disease. Consistent with
this notion, fecal lactoferrin (a marker of fecal leukocytes) and
IL-8 (a neutrophil chemoattractant) are elevated in patients with
severe disease (9). Furthermore, patients with specific interleu-
kin-8 (IL-8) promoter polymorphisms are reported to be more
susceptible to C. difficile disease (10, 11). Because the host inflam-
matory response is felt to be a major component of CDI disease
manifestations, several novel approaches to mitigating inflamma-
tion in CDI are being explored (12–15).
In vitro and in vivo models indicate that TcdA and TcdB can
directly induce inflammatory cytokine release. Indeed, inflamma-
tion occurs within the first few hours after direct toxin injection
into a murine ileal loop model, and blocking the inflammatory
cascade markedly attenuates mucosal injury (16, 17). Similarly,
purified C. difficile toxins induce the release of inflammatory cy-
tokines from cultured intestinal epithelial cells. In particular, IL-8,
a neutrophil chemoattractant known to be regulated by the p38
pathway, is highly induced by toxin exposure in vitro (16–18).
These findings suggest that p38 kinase is a critical early driver of
the neutrophilic inflammatory response (16, 17).
Of the four main isoforms of p38 kinase, p38 is most widely
distributed and is most implicated in cell-mediated inflammatory
responses (19, 20). The kinase is activated by a number of extrinsic
and intrinsic stimuli, including conditions that damage essential
cellular components, like UV radiation and oxidative stress. Once
activated, p38 can phosphorylate multiple downstream effec-
tors. Depending on the stimulus or the cell type, these effectors
affect proliferation, inflammation, or cell death. Indeed, TcdA is
reported to cause p38-dependent necrosis of monocytes, apopto-
sis of colonocytes, and induction of IL-8, cyclooxygenase-2 and
prostaglandin E2 synthesis in treated cells (16, 21, 22). In most
circumstances, the major effector mediating p38-dependent in-
flammation is mitogen-activated protein kinase (MAPK)-acti-
vated protein kinase-2 (MK2), a member of the MK subfamily of
calcium/calmodulin-dependent kinases. MK2 increases the ex-
pression of IL-8, tumor necrosis factor alpha (TNF-), and other
inflammatory cytokines (23–25). Activated MK2 phosphorylates
many downstream targets, such as tristetraprolin (TTP), lympho-
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cyte-specific protein tyrosine hydroxylase, and 5-lipoxygenase
(24, 26). Among the best-studied MK2 targets is heat shock pro-
tein 27 (Hsp27). Upon MK2-induced phosphorylation, Hsp27
undergoes a conformational change, shifting from large multim-
ers to dimers to affect chaperone function and interactions with
the actin cytoskeleton (27, 28). Like p38 kinase, which is the target
of several novel anti-inflammatory agents, MK2 kinase is a target
of several anti-inflammatory drug discovery programs (29–34).
Here, we demonstrate that TcdA and TcdB cause p38-depen-
dent activation of MK2 in toxin-exposed cells, colons of infected
animals, and stools of humans with CDI. We describe that MK2
inhibition blocks toxin-induced cytokine release from toxin-ex-
posed enterocytes. Inhibition of these kinases does not interfere
with toxin activity but markedly attenuates the subsequent in-
flammatory cytokine release. Drugs that disrupt the actin cyto-
skeleton also cause p38- and MK2-dependent IL-8 secretion, sug-
gesting that disruption of the actin network is the initiating event
in C. difficile toxin-induced inflammation. Furthermore, we show
that p38 and MK2 are activated in colons of infected animals and
in human CDI patients. Our results indicate that toxin-induced
MK2 activation drives C. difficile-associated inflammatory re-
sponses and suggest that MK2 inhibition may attenuate intestinal
inflammation and thereby improve disease outcome in patients
with CDI.
MATERIALS AND METHODS
Reagents and antibodies. TcdA was purchased from List Laboratories
(Campbell, CA). Recombinant TcdB was purified from Bacillus megate-
rium, the genome of which encodes full-length TcdB-(histidine)6 under
the control of a xylose-inducible promoter (kindly provided by Lacy Bor-
den) (35). B. megaterium was grown to an optical density at 600 nm
(OD600) of0.6 before addition of L-xylose (5 g/liter), which induced the
expression of TcdB. After incubating for a further 3 h at 30°C, cells were
pelleted and sonicated in lysis buffer (0.1% Triton X-100 in phosphate-
buffered saline [PBS] containing protease inhibitor cocktail). The debris
was pelleted, and the TcdB-His was purified by sequential nickel and gel
filtration column chromatography. Aliquots were frozen at 80°C at a
concentration of 0.4 mg/ml in phosphate-buffered saline until further
use. SB203580, SP600125, latrunculin B, cytochalasin B, nocodazole, and
dimethyl sulfoxide (DMSO) were purchased from Sigma-Aldrich (St.
Louis, MO). The MK2 inhibitor, PHA-781089, was a gift of Pfizer (36).
Chemical inhibitors were diluted to 10 mM in DMSO and stored at
20°C until further use. Antibodies recognizing p38, phospho-p38,
Hsp27, phospho-Hsp27, and total actin were purchased from Cell Signal-
ing Technology (Danvers, MA), and monoclonal antibody recognizing
the nonglucosylated form of Rac1 was from BD Transduction Labs (clone
102; 610650; San Jose, CA). Complete Mini protease inhibitor cocktail
tablets were purchased from Roche. One tablet was dissolved in 15 ml of
buffer during toxin purification and cell lysis. H29 (human colon adeno-
carcinoma; ATCC HTB-38), Caco2 (human colorectal adenocarcinoma;
ATCC HTB-37), and T84 (human colorectal carcinoma; ATCC CCL-
248) cells were obtained from the ATCC and were maintained at 37°C and
5% CO2 in Dulbecco’s modified essential medium (DMEM) (Mediatech,
Manassas, VA) supplemented with 10% fetal bovine serum (FBS) (Hy-
Clone, Rockford, IL) and 0.1% penicillin-streptomycin (Mediatech, Ma-
nassas, VA).
Westernblotting.Following experimental treatments, cells were lysed
in lysis buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM Na2EDTA,
1 mM EGTA, 1% Triton, 2.5 mM sodium pyrophosphate, 1 mM -glyc-
erophosphate, 1 mM Na3VO4, 1 g/ml leupeptin, 1 protease inhibitor
cocktail). Colonic tissues excised from hamster or mice were prepared for
protein immunoblotting by suspending tissue pieces in 10-fold volumes
of lysis buffer and then homogenizing with a handheld tissue disruptor
(Fisher Scientific, Pittsburgh, PA). After centrifuging to remove particu-
lates, protein concentrations were determined and equalized by adding
lysis buffer.
In each experiment, equal amounts of protein were mixed with SDS-
PAGE loading buffer and then resolved on a 4 to 15% Tris-HCl gel (Bio-
Rad Corp., Hercules, CA) before transfer to polyvinylidene difluoride
(PVDF) membranes (Invitrogen Corp, Carlsbad, CA). Membranes were
probed with corresponding primary antibodies (1:1,000) and anti-rabbit
or anti-mouse alkaline phosphatase-conjugated secondary antibodies
(Invitrogen Corp, Carlsbad, CA). Membranes were washed five times
with wash buffer (WesternBreeze; Invitrogen) for 5 min each, twice with
water for 5 min, and then developed using the WesternBreeze kit protocol
(Invitrogen). For comparisons of multiple phosphoproteins, membranes
were washed three times for 5 min in wash buffer (WesternBreeze) and
reprobed with additional antibodies. Where indicated, equal fractions of
lysates from the same experiment were run on separate gels and probed
with the corresponding primary antibodies.
Phospho-MK2 EIA. We developed a sandwich enzyme immunoassay
(EIA) to quantify pMK2 in fecal samples. To prepare enzyme-linked im-
munosorbent assay (ELISA) plates, each well was coated with goat anti-
body against total MK2 (C-18; sc-6221; Santa Cruz Biotechnology, Santa
Cruz, CA) at a concentration of 400 ng/ml in 100 l 50 mM carbonate
buffer, pH 9.5 (BD OptEIA kit; 550534; BD Biosciences, San Jose, CA).
The following day, plates were blocked with 200 l coating buffer
(OptEIA kit) for at least 2 h. To process stool samples, approximately 100
mg fecal material was suspended in an equal volume of 1 lysis buffer
containing phosphatase inhibitors (9803; Cell Signaling Technology) to
which one tablet of Complete Mini protease inhibitor (Roche) per 15 ml
was added. The samples were vortexed vigorously for 2 min and then
centrifuged for 5 min at 10,000  g to pellet debris. Supernatants were
transferred to a new tube and used immediately for pMK2 detection or
stored at80°C until use. To detect pMK2 in processed fecal samples, 20
l was added to 80 l 1 lysis buffer per well, and the plates were incu-
bated at 4°C for 24 h. After washing three times with wash buffer (OptEIA
kit), rabbit anti-pMK2 (Thr222) antibody (sc-31675; Santa Cruz Biotech-
nology) was added at 200 ng/ml and incubated for 2 h at room tempera-
ture. After washing each well four times with 300 ml wash buffer (OptEIA
kit), 100 l of horseradish peroxidase (HRP)-conjugated anti-rabbit an-
tibody diluted 1:5,000 was added per well and incubated for 1 h at room
temperature. The wells were washed 6 times with 300 ml of wash buffer,
and then 100 ml of peroxidase substrate was added (3,3=,5,5=-tetrameth-
ylbenzidine [TMB]; T8665; Sigma). The reaction was stopped after ap-
proximately 30 min at room temperature by the addition of 50 l 2 M
sulfuric acid, and the signal was read at 450 nm after subtracting back-
ground levels on an automated microtiter plate spectrophotometer. A
standard curve using recombinant phosphorylated MK2 (American Re-
search Products, Waltham, MA) was used to quantify the sample pMK2. A
low positive internal control (75 to 100 pg/ml) was included on each
microtiter plate run to measure reproducibility. Stools were also tested for
IL-8 (Quantikine human CXCL8/IL-8; R&D Systems, Minneapolis, MN)
and lactoferrin (IBD Scan; TechLab, Blackburn, VA) according to the
manufacturer’s instructions.
Cytotoxicity testing. Stool or broth culture filtrates were tested for
neutralizable cytotoxicity using HT-29 adenocarcinoma tissue-cultured
cells (HTB 38; American Type Culture Collection) grown in microtiter
plates with a TcdB positive control and compared to noninoculated cells
(19). The antitoxin neutralizes TcdB-induced cytotoxicity (Clostridium
difficile Toxin/Antitoxin kit; TechLab, Blacksburg, VA), and results were
considered final after 48 h. This cell line is highly sensitive to C. difficile
toxins (20, 21).
Culture PCR. Stool samples were additionally cultured anaerobically
for 48 h on taurocholate cefoxitin cycloserine mannitol agar (TCCMA),
which is suitable forC. difficile vegetative and spore forms (22). TCCMA is
a modification of commonly used C. difficile isolation agar TCCFA, with
replacement of fructose by mannitol so as to limit the number of clostrid-
Bobo et al.
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ial species (37). Characteristic colonies (consisting of anaerobic, large,
Gram-positive rods) were then purified and subcultured to prereduced
broth, and filtrates were tested for neutralizable cytotoxicity as described
in the section on cytotoxicity testing. In addition, each isolate was tested
for tcdB by suspending colonies in water and heating (95°C for 15 min),
and the supernatant was subjected to PCR using published primers
tcdB-1F (5= GAAGGTGGTTCAGGTCATAC) and tcdB-1R (5= CATTTT
CTAAGCTTCTTAAACCTG) (23). The PCR products were visualized in
ethidium-stained agarose gels. If the first PCR was negative, two other
published primer sets were tested: TcdB-F (5= AGCAGTTGAATATAGT
GGTTTAGTTAGAGTTG) and TcdB-R (5= CATGCTTTTTAGTTTCTG
GATTGAA) (24) as well as TB1-F (5= GAGCTGCTTCAATTGGAGAGA)
and TB2-R (5= GTAACCTACTTTCATAACACCAG) (25).
Hamster andmurineC. difficile infections.All animal protocols were
approved by the Institutional Animal Care and Use Committee of the
Washington University School of Medicine. Like humans, hamsters and
mice become much more susceptible to C. difficile infection after antibi-
otic treatment. In the case of hamsters, a single intraperitoneal injection of
clindamycin 2 days prior to infection renders the animals highly suscep-
tible. In the case of mice, an antibiotic cocktail is utilized as described
below. Six male Syrian golden hamsters, 5 to 6 weeks old (purchased from
Harlan Laboratories, Indianapolis, IN), were given a single intraperito-
neal injection of clindamycin (30 mg/kg) 1 day before challenge, which
makes the animals much more susceptible to C. difficile infection (38).
The following day, animals were gavaged with either 103 or 104 CFU of the
highly virulent C. difficile strain NAP1. Thirty-six hours later, hamsters
had moist stools, appeared ill, and were sacrificed by 100% carbon dioxide
exposure. Colons were removed and processed for protein immunoblot-
ting as described above.
Four male C57BL/6J mice, 6 to 8 weeks old (purchased from Jackson
Laboratories, Bar Harbor, MN), were pretreated with antibiotics to render
animals susceptible to C. difficile infection (kanamycin [0.4 mg/ml], gen-
tamicin [0.035 mg/ml], colistin [850 U/ml], metronidazole [0.215 mg/
ml], and vancomycin [0.045 mg/ml]) in drinking water for 5 days as
previously described (39). Two days before infection, all mice were
changed to regular autoclaved water lacking these antibiotics, and then 1
day before infection they received a single dose of clindamycin (30 mg/kg
of body weight) intraperitoneally. Mice were gavaged on day 0 with 104
CFU of the NAP1 strain. Mice were sacrificed 48 h after infection, at which
point they had developed loose stools, hunched appearance, and ruffled
fur. Colons were immersed in OCT, snap-frozen in liquid nitrogen, and
then sectioned with a cryotome. Specimens were fixed by immersion for 5
min in ice-cold acetone, air dried, and then rehydrated by immersing
twice in PBS for 5 min each.
Slides were stained with antibodies against phospho-MK2 (3007; Cell
Signaling Technology, Danvers MA) or CD45 (clone 30-F11; BioLegend,
San Diego, CA) followed by fluorescently labeled secondary antibodies
and then were mounted in media containing 4=,6-diamidino-2-phenylin-
dole (DAPI). Slides were imaged by indirect immunofluorescence under
400 magnification using a Zeiss epifluorescence microscope, and im-
ages were captured using AxioVision software.
Human patients with C. difficile infection. Loose stools submitted
for C. difficile testing were obtained from 100 patients, aged 18 to 95 years
and hospitalized at Barnes Jewish Hospital, St. Louis, MO, between 2010
and 2011. The use of deidentified samples precluded our ability to glean
any knowledge of concurrent usage of anti-C. difficile antibiotics or anti-
inflammatory medications. This component of the study was approved by
the Institutional Review Board of Washington University School of Med-
icine. For the purposes of the current study, we definedC. difficile-positive
samples as those that yielded a cytotoxin-positive C. difficile colony from
culture. We did not exclude any samples and directly compared inflam-
matory markers fromC. difficile cytotoxin-positive and -negative samples.
Statistical analyses. Data were processed and analyzed using Graph-
Pad Prism version 5.00 for Windows (GraphPad software). Comparisons
of pMK2, IL-8, and lactoferrin levels to the presence of toxigenic C. diffi-
cile were made using a 2-tailed Wilcoxon signed rank test, and biomarker
levels were compared to each other using Spearman correlations (Stat-
View, SAS). Sensitivity, specificity, and positive and negative predictive
values for pMK2 and IL-8 were determined after a cutoff was assigned
using receiver operator characteristic curve (ROCC) analysis (GraphPad
Prism 5); those for lactoferrin were determined using the manufacturer’s
recommendations. These and other statistical analyses are explained in
the footnote to the table for respective variable comparisons, with P 
0.05 considered significant.
RESULTS
p38 andMK2 are activated in enterocytes andmonocytes in re-
sponse to TcdA and TcdB. We wished to determine the ability of
TcdB to activate p38 and MK2 in cultured human enterocytes.
The data presented here demonstrate the effects of TcdB on
HT-29 cells, which are derived from large intestinal epithelium
and have been used as a model of proinflammatory gene expres-
sion (40). The data presented here focus on TcdB, because this
toxin is generally thought to be most relevant to disease (41, 42).
However, we have found that both TcdA and TcdB caused phos-
phorylation of p38 and MK2 in T84 and Caco-2 cells, which are
also human intestinal cell lines (data not shown).
HT-29 cells were treated with TcdB at increasing concentra-
tions (0 to 80 ng/ml TcdB) or for increasing amounts of time (0 to
360 min) (Fig. 1B). The cells were then lysed and subjected to
SDS-PAGE followed by protein immunoblotting to detect phos-
phorylated p38 or phospho-Hsp27 as a specific marker of MK2
activation (36). We compared p38 and MK2 activation to nong-
lucosylated Rac1 signal. TcdB transfers a glucose moiety to Rac1,
resulting in loss of reactivity with monoclonal antibody clone 102
(BD Transduction Laboratories), therefore it is a good indicator of
the toxin effect on an intracellular target. Treatment of HT29 cells
demonstrated that Rac1 reactivity began to decrease at 0.8 to 3
ng/ml TcdB (Fig. 1A). In contrast, p38 and Hsp27 were phosphor-
ylated at toxin concentrations as low as 0.8 ng/ml and became
maximal at approximately 16 ng/ml (Fig. 1A). These findings in-
FIG 1 p38 and MK2 are activated by toxin exposure. (A) HT-29 cells were
exposed to TcdB at the indicated concentrations for 2 h. Cell lysates were
subjected to SDS-PAGE and then immunoblotted for phospho-p38, phospho-
Hsp27, or nonglucosylated Rac1. (B) HT-29 cells were treated with 20 ng/ml
TcdB for the indicated times, and then cell lysates were collected and immu-
noblotting performed as described for panel A.
MK2 Kinase in C. difﬁcile
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dicate that p38 and MK2 activation are very sensitive to intracel-
lular toxin activity. Similarly, both kinases were activated within
60 min of toxin addition, when the Rac1 signal first began to fade,
indicating that kinase activation occurs rapidly after toxin inter-
nalization (Fig. 1B). Similarly, TcdA causes phosphorylation of
p38 and MK2 at the lowest concentrations affecting Rac1 gluco-
sylation in T84 cells and with similarly rapid kinetics (see Fig. S1 in
the supplemental material).
In summary, p38 and MK2 kinase activity are induced at the
lowest toxin concentrations and the earliest time points at which
TcdB has a measurable effect on HT29 cells.
Toxin-induced MK2 activation is p38 dependent. We next
confirmed that toxin-induced MK2 activation was attributable to
p38 and not due to JNK, another kinase known to be activated by
cellular stress. To demonstrate that p38 activity was necessary for
MK2 phosphorylation and activation, HT-29 cells were incubated
with kinase inhibitors starting 30 min prior to TcdB exposure. p38
inhibitor SB203580 and inhibitor III diminished TcdB-induced
MK2 activation, as indicated by a marked decrease in phospho-
Hsp27 in treated cells. However, the JNK kinase inhibitor
SP600125 had no effect on TcdB-induced Hsp27 phosphoryla-
tion. Finally, the MK2-specific inhibitor PHA-781089 markedly
diminished TcdB-induced MK2 activity. These results confirmed
that TcdB-induced MK2 activity was p38 dependent. To exclude
the possibility that this effect was caused by inhibition of toxin
internalization or transport, we confirmed that neither inhibitor
blocked TcdB effect on Rac1 glucosylation (Fig. 2). We extended
these findings to show that TcdA induced p38-dependent MK2
activation in T84 cells, revealing that both toxins result in p38-
dependent MK2 activation (see Fig. S2 in the supplemental mate-
rial).
p38 and MK2 inhibition blocks toxin-induced IL-8 and
GRO release fromHT-29 cells. We next asked if p38 inhibition
of toxin-induced cytokine production by cultured enterocytes is
mediated through p38-dependent activation of MK2. IL-8 and
GRO (also known as CXCL-1) are both neutrophil chemoattrac-
tants, binding to CXCR-2 receptors on neutrophils and macro-
phages, signaling their recruitment to the site of cytokine release.
HT-29 cells were exposed to TcdB in the absence of inhibitor or in
the presence of p38 inhibitor or a specific MK2 kinase inhibitor.
The p38 inhibitor SB203580 efficiently blocked toxin-induced
IL-8 and GRO secretion by HT-29 cells. MK2 kinase inhibitor
PHA-781089 completely inhibited TcdB-induced IL-8 and GRO
secretion induced by HT-29 cells (Fig. 3A and B). Similar effects
on IL-8 secretion were seen when HT-29 cells were treated with
TcdA in the presence or absence of p38 or MK2 kinase inhibitors
(see Fig. S3 in the supplemental material). These results indicate
that C. difficile toxin-induced inflammatory cytokine release from
cultured enterocytes depends on activation of the p38-MK2 ki-
nase cascade.
Neither p38 nor MK2 inhibition prevents toxin internaliza-
tionor affectsRac1 glucosylation.Having demonstrated that p38
or MK2 inhibition decreases IL-8 production, we next excluded
the possibility that these kinases were required for toxin internal-
ization or activity, particularly as p38 inhibition has been reported
to affect intracellular transport of Shiga toxin (43). HT-29 cells
were pretreated with either kinase inhibitor and then exposed to
TcdB in the presence of kinase inhibitor. The cells rounded to the
same extent and with the same kinetics independent of kinase
inhibition (not shown). Furthermore, neither kinase inhibitor
impaired toxin-induced Rac1 glucosylation, as demonstrated by
loss of reactivity with monoclonal antibody 102, which is specific
FIG 2 Toxin-induced MK2 activation is p38 dependent. HT-29 cells were
preincubated with either 0.1% DMSO, p38 inhibitor SB203580 (2.65M), p38
inhibitor III (0.5 M), JNK kinase inhibitor SP600125 (25 M), or MK2
inhibitor PHA-781089 (20M) for 30 min and then exposed to either no toxin
or TcdB at 20 ng/ml for 2 h. Cell lysates were subjected to SDS-PAGE followed
by immunoblotting for phospho-p38, phospho-Hsp27, or nonglucosylated
Rac1.
FIG 3 Toxin-induced cytokine release is p38 and MK2 dependent. HT-29 cells were preincubated with p38 inhibitor SB203580 (2.65 M) or MK2 inhibitor
PHA-781089 (20 M) for 30 min and then exposed to TcdB (20 ng/ml) for 12 h in the presence of the kinase inhibitors. The supernatants were harvested, and
IL-8 concentration (A) or GRO concentration (B) was determined by ELISA (**, P 0.01; ***, P 0.001).
Bobo et al.
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for the unmodified form. In contrast, bafilomycin A and ammo-
nium chloride, both of which block endosome acidification and
therefore toxin access to the cytoplasm, blocked Rac1 glucosyla-
tion (Fig. 4). Similar results were seen with the fibroblast-like
HeLa cell line, where p38 or MK2 inhibition did not affect TcdB-
mediated Rac1 glucosylation (see Fig. S4 in the supplemental ma-
terial).
Actin-disrupting agents cause MK2 activation and IL-8 re-
lease. The p38-MK2 kinase pathway is activated by diverse stim-
uli, including extrinsic and intrinsic cellular injuries (44, 45). For
example, we previously demonstrated that cellular injury caused
by Shiga toxin results in p38-MK2 kinase activation and IL-8 re-
lease (46). Shiga toxin damages the ribosome, impairing protein
translation and ultimately causing cell death. C. difficile toxins
have an entirely different mechanism of cellular injury. Specifi-
cally, TcdA and TcdB glucosylate and inactivate the small GTPases
Rho, Rac, and CDC42. Among the resulting effects, one of the
most striking outcomes is disruption of the actin cytoskeleton. We
wondered whether cytoskeletal disruption could be a mechanism
whereby the C. difficile toxins activate p38 and MK2 kinases and
therefore directly tested the effects of actin- and microtubule-dis-
rupting agents on p38 and MK2 kinase phosphorylation. HT-29
colonic epithelial cells were treated with toxin TcdB or small-mol-
ecule compounds that disrupt the actin cytoskeleton (latrunculin
B or cytochalasin B) or that disperse microtubules (nocodazole).
MK2 activation was assessed by detecting the phosphorylated
form of MK2 substrate Hsp27. Cells exposed to actin-disrupting
agents showed activation of MK2 at levels comparable to those
caused by TcdB as assessed by Hsp27 phosphorylation, while the
microtubule-disrupting agent nocodazole did not result in in-
creased Hsp27 phosphorylation (Fig. 5A). Furthermore, actin dis-
ruption with cytochalasin B increased IL-8 secretion by HT-29
cells to an even greater extent than did TcdB, while the microtu-
bule-disrupting agent nocodazole did not significantly increase
IL-8 release. Pretreatment of cells with the highly specific MK2
inhibitor (36) completely abolished IL-8 secretion induced by
toxin or actin disruption (Fig. 5B). These results suggest that dis-
ruption of the actin cytoskeleton is one means whereby the C.
difficile toxins can activate p38 and MK2 and incite an inflamma-
tory response.
Phospho-MK2 is detected in tissues of infected animals. We
next determined if the p38-MK2 pathway was activated in vivo
during C. difficile infection. Syrian golden hamsters have been
used as a model forC. difficile infection. Pretreatment with a single
dose of clindamycin renders the animals exquisitely susceptible to
C. difficile. As has previously been reported, we found that infec-
tion of Syrian golden hamsters with 1,000 CFU of the NAP1 C.
difficile strain resulted in 100% mortality (n  6). As has been
described previously, necropsy demonstrated a grossly enlarged
and hemorrhagic cecum (47, 48). Histopathologic examination
showed diffuse disruption of the epithelium, hemorrhage into the
submucosal tissues, and a marked neutrophilic infiltrate (not
shown). To determine if p38 and MK2 were activated during acute
infection, hamsters were sacrificed 36 h after infection with either
103 or 104 CFU of the virulent NAP1 C. difficile strain. Compared
to an uninfected animal, colons from hamsters infected with C.
difficile had increases in phospho-p38, phospho-MK2, and the
phosphorylated form of MK2 substrate Hsp27 (Fig. 6A). Phos-
phorylated p38 and MK2 were also detected in colons of infected
mice by protein immunoblotting (not shown). Immunofluores-
cence staining demonstrated MK2 activation in intestinal epithe-
lial cells. There was a brisk inflammatory infiltrate, as evidenced by
the presence of CD45-positive cells, a marker for cells of hemato-
poietic origin, but these cells did not label with anti-pMK2
(Fig. 6B). These findings are consistent with the model that toxin-
induced damage activates p38-MK2 in enterocytes, resulting in
IL-8 release and subsequent inflammatory cell recruitment.
Phospho-MK2 is detected in fecal filtrates of patients withC.
difficile infection. Previous investigators demonstrated that fecal
inflammatory markers were elevated in patients with CDI. In par-
ticular, fecal IL-8 and fecal lactoferrin were more highly elevated
in patients with severe disease than in patients with mild disease
(9). We investigated the possibility that the p38/MK2 pathway is
similarly activated in patients with C. difficile infection. A conve-
nience sample of 100 stool specimens submitted for C. difficile
testing was tested for the presence of phospho-MK2, lactoferrin,
and IL-8. C. difficile toxin immunoassay testing was performed in
the clinical microbiology laboratory, and stools were frozen. Sub-
sequently, the C. difficile status was verified in our laboratory by
culture and in vitro toxin testing. Toxigenic C. difficile was de-
tected in 15% of samples submitted for testing.
As described in Materials and Methods, our laboratory devel-
oped an enzyme immunoassay to detect phospho-MK2 and found
the ELISA to be linear from 30 pg/ml to 5 ng/ml of pMK2 stan-
dard. The sensitivity of the ELISA compared well to detection by
immunoblotting, which had a sensitivity of 150 pg/ml (data not
shown). Using this assay and commercially available ELISAs, we
quantitated pMK2, IL-8, and lactoferrin in stools submitted to the
clinical microbiology laboratory.
Although there was a large degree of variation between sam-
ples, pMK2, IL-8, and lactoferrin levels were significantly higher in
filtrates from patients with stool positive for cytotoxigenic C. dif-
ficile than in samples fromC. difficile-negative patients (P 0.003,
0.012, and 0.048, respectively, by Wilcoxon signed rank test). Sev-
eral of the C. difficile-negative patients had detectable levels of
phospho-MK2, IL-8, or lactoferrin in the stool. These patients all
had loose stools, which was the reason for sending their samples
for C. difficile testing. Our results suggest that many of them had
associated intestinal inflammation. Nevertheless, the degree of
pMK2 elevation and the percentage of patients with detectable
pMK2 were both greater in C. difficile-infected patients than in C.
difficile-negative patients (Fig. 7). As an alternate method of com-
FIG 4 p38 and MK2 inhibition do not interfere with toxin transport or activity.
HT-29 cells were preincubated with either 0.1% DMSO, p38 inhibitor SB203580
(2.65M), MK2 inhibitor PHA-781089 (20M), bafilomycin (5M), or ammo-
nium chloride (20 mM) for 30 min. TcdB then was added at a concentration of 20
ng/ml, and the cells were incubated for a further 2 h. Cell lysates were subjected to
SDS-PAGE and immunoblotting for actin or nonglucosylated Rac1.
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paring the samples, we set positive and negative cutoff values for
each inflammatory parameter. A cutoff for pMK2 of 	1 pg/ml
was considered positive, revealing that 73% of C. difficile-positive
samples and 38% of C. difficile-negative samples were positive for
pMK2. Using a two-tailed Fisher’s exact test, this difference was
statistically significant (P  0.021) (Table 1). Similarly, a cutoff
value for IL-8 was set at 3.5 pg/ml based on the manufacturer’s
information, yielding a positive IL-8 result in 87% of C. difficile
FIG 5 Actin-disrupting agents cause MK2 activation and IL-8 secretion. (A) HT-29 cells were treated for 2 h with TcdB (20 ng/ml), latrunculin (5 M),
cytochalasin B (25 M), or nocodazole (10 g/ml). Cell lysates were then subjected to SDS-PAGE followed by immunoblotting for actin or for phosphorylated
Hsp27. The exposed film was then scanned, and band intensity was determined using ImageJ. (B) HT-29 cells were treated with TcdB (20 ng/ml), cytochalasin
B (25M), or nocodazole (10g/ml) in the presence of either 0.1% DMSO, p38 inhibitor SB203580 (2.65M), or MK2 inhibitor PHA-781089 (20M) for 12
h. The supernatants were then removed, and IL-8 was detected by ELISA.
FIG 6 C. difficile infection causes p38 and MK2 activation in hamster and murine colon. (A) The day after a single dose of clindamycin, hamsters were infected
either with 104 or 103 CFU of C. difficile strain NAP1. Hamsters were sacrificed at 48 h after infection, their colons removed, and lysates subjected to SDS-PAGE
followed by immunoblotting for phsopho-p38, phospho-MK2, phospho-Hsp27, or actin. (B) Mice were infected withC. difficile after 7 days of pretreatment with
oral kanamycin, gentamicin, colistin, metronidazole, and vancomycin and a single dose of clindamycin 1 day prior to infection. Forty-eight h later the animals
were sacrificed and colons labeled with antibodies against phospho-MK2 (red; Alexa Fluor 596) or CD45 (green; Alexa Fluor 488).
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cytotoxin-positive and 58% of C. difficile-negative values (P 
0.043). Finally, using a lactoferrin cutoff of 7.25 g/ml (as indi-
cated by the manufacturer’s information) yielded nonsignificant
correlation between lactoferrin positivity and detectable cytotoxin
(P  0.134), being detected in 87% of C. difficile cytotoxin-posi-
tive samples and 63% of cytotoxin-negative samples.
In summary, the analysis demonstrates that pMK2 levels are
higher in fecal samples of C. difficile patients than in C. difficile-
negative patients, andC. difficilepatients were much more likely to
have detectable pMK2 in their feces than C. difficile-negative pa-
tients, supporting a role for this kinase in toxin-induced intestinal
inflammation.
DISCUSSION
Hospital-acquired Clostridium difficile infection is now consid-
ered a public health emergency in the United States, Canada, and
Europe. Recently, C. difficile infection (CDI) incidence was re-
portedly 21% higher than methicillin-resistant Staphylococcus au-
reus infection as a cause of hospital-acquired infection and as
common as hospital-wide bloodstream infections (49). Symp-
toms of CDI range from mild diarrhea to the formation of pseu-
domembranous lesions, toxic megacolon, sepsis, and death. Op-
portunistic CDI is most strongly associated with hospitalization
and prolonged antibiotics use, as C. difficile can only colonize the
gut if the normal intestinal microbiota is absent or disturbed.
The full spectrum of CDI symptoms can be largely attributed to
the production of its two toxins, toxin A (TcdA) and toxin B
(TcdB), as nontoxigenic strains have been found to be avirulent in
both human and animal models. Both toxins cause disruptions in
the actin cytoskeleton and tight junctions of the host cell, thus
compromising transepithelial resistance and the integrity of the
epithelial barrier. Additionally, the toxins directly incite an in-
flammatory response in vitro (42) and in vivo (14, 50).
Current therapies for CDI are unsatisfactory. Only three anti-
biotics have demonstrated clinical efficacy. Metronidazole is rec-
ommended as the first-line agent in mild to moderate CDI (51).
Treatment failures occur in 15 to 20% of cases (52). Oral vanco-
mycin is recommended in severe disease or in cases of metronida-
zole failure (53, 54), but it fails to cure in up to 15% of cases (55).
Fidaxomicin has just been approved as a third antibiotic for the
treatment of CDI, but its global cure rate is only 77% (56). In
addition, this drug is very costly, and its efficacy may have some
variability depending on the C. difficile strain type. Regardless of
therapy, patients remain symptomatic for an average of 5 days
after starting antibiotics, and some will progress to severe or ful-
minant disease and die despite standard-of-care medical manage-
ment (57). Progression and death from CDI may be due to an
uncontrolled, toxin-driven inflammatory response, resulting in
massive intestinal necrosis. The intense inflammatory response
incited by C. difficile may be predominantly pathogenic, contrib-
uting to disease without significantly benefitting the host. In this
regard, it is important to determine if the toxin-induced inflam-
matory response can be therapeutically modulated without im-
pairing beneficial immune responses to the infection.
Biomarkers of inflammation, such as IL-8, a chemokine of
neutrophils, and the neutrophil lactoferrin, have been assessed in
the context of human CDI, where they are associated with more
severe disease (9, 58–60). To date, cellular signaling molecules
such as p38 and MK2 kinases have not been evaluated in patients
with CDI. However, previous investigators found that p38 was a
major regulator of inflammation and cell death induced by C.
difficile, indicating that this pathway was essential to toxin-in-
duced inflammation (17, 21, 22, 61). This kinase is widely ex-
pressed and regulates cellular response to injury. Its activation can
result in proliferation, apoptosis, or inflammation depending on
the stimulus and the cell type. p38 inhibitors have been explored as
potential anti-inflammatory agents in a number of diseases; how-
ever, none of these compounds has yet to be licensed due to prob-
lems with efficacy or tolerability (62). For that reason, focus has
FIG 7 Median phospho-MK2, IL-8, and lactoferrin levels are higher in feces from C. difficile patients than in samples from C. difficile-negative patients. One
hundred stool samples submitted forC. difficile testing to the clinical laboratory were analyzed for the presence of cytotoxin-producingC. difficile. From the same
samples, phosphorylated MK2, IL-8, and lactoferrin levels were measured by ELISA, and each was compared to a standard curve. Median values are indicated by
the thick black bar.
TABLE 1 Biomarkers in patients with toxigenic C. difficile compared to







(n 85) P valuea
pMK2 (	1 pg/ml) 11 (73) 32 (38) 0.021*
IL-8 (	3.5 pg/ml) 13 (87) 49 (58) 0.043*
Lactoferrin (	7.25 g/ml) 13 (87) 54 (63) 0.134
a Comparisons were done with two-tailed Fisher’s exact test. *, Correlation is significant
at the 0.05 level.
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shifted to MK2 kinase, a substrate of p38 which is more narrowly
expressed and is felt to be more specifically involved in stress-
induced inflammation (34, 63). pMK2, whose precursor is p38,
belongs to the calcium-calmodulin kinase superfamily (64). After
activation of p38 by a variety of stressors, pMK2 phosphorylates
specific molecules which regulate the actin cytoskeleton and sta-
bilize cytokine mRNA transcripts (34, 65, 66). mRNA transcripts
for IL-8 and TNF- can then mediate a number of downstream
effects, including neutrophil chemotaxis, vasodilation, tissue
edema, and cellular apoptosis. Several MK2 kinase inhibitors are
currently in development for treatment of inflammatory diseases,
and it is hoped that these compounds will retain the anti-inflam-
matory activity of p38 inhibitors while lacking the toxicities that
may relate essential noninflammatory p38 activities (30, 34).
We find that TcdA and TcdB cause p38-dependent activation
of MK2 and demonstrate that MK2 inhibition in vitro completely
blocks toxin-induced IL-8 release from both enterocytes and
monocytes despite the observation that MK2 inhibition does not
affect the toxin-induced effects on the cell. These toxins inactivate
the Rac and Rho family of small GTPases, resulting in disruption
of the actin cytoskeleton. Treatment of cultured intestinal epithe-
lial cells with actin- but not microtubule-disrupting agents also
causes p38-MK2 activation and increased IL-8 production, sug-
gesting that actin disassembly is the mechanism of inflammatory
kinase activation in toxin-exposed cells. We demonstrate that the
p38-MK2 pathway is activated in the intestines of infected ani-
mals. To determine whether pMK2 arose from damaged intestinal
mucosa or from infiltrating myeloid cells, immunofluorescence
microscopy was performed and demonstrated that pMK2 was de-
tected in nonmyeloid cells. These findings are consistent with the
notion that toxin-induced cellular injury results in activation of
p38-MK2 in intestinal mucosa, resulting in increased inflamma-
tory cytokine production and subsequent infiltration of pMK2-
negative myeloid cells. Finally, we demonstrate that phosphory-
lated MK2 is present in the stools of infected patients, suggesting
that the pathway is activated in at least a subset of individuals
with CDI.
C. difficile toxin A (TcdA) is known to induce p38-dependent
cytokine production when instilled directly into mouse ileum (17,
67). The present study is the first to demonstrate that MK2 is the
downstream mediator of toxin-induced p38-dependent cytokine
production. Moreover, this is the first study to demonstrate that
the pathway is activated in C. difficile-infected animals and hu-
mans.
In human CDI patient samples, we found a significant associ-
ation of pMK2 elevation with the presence of toxigenic C. difficile.
There was considerable variability of all inflammatory markers
among patients, and phospho-MK2, IL-8, and lactoferrin were
detected in a significant fraction of patients without C. difficile
infection. All of these patients had gastrointestinal symptoms. In-
flammatory cytokine gene expression can be detected in fecal ex-
tracts from patients with other bacterial causes of enteritis (68,
69). Inflammatory cytokines and lactoferrin are also elevated in
the feces of patients with active inflammatory bowel disease (9, 70,
71). Like inflammatory cytokine levels, fecal pMK2 may be a gen-
eral indicator of intestinal inflammation. MK2 is activated by
Shiga toxin and during influenza A virus infection of cultured cells
(46). Whether the p38-MK2 pathway plays a more general role in
pathogen-induced inflammation remains to be determined. Nev-
ertheless, pMK2 elevation was significantly correlated with C. dif-
ficile infection in our unbiased collection of stool samples sent for
C. difficile testing, indicating that this proinflammatory pathway is
activated in the majority of patients with C. difficile infection.
Our results indicate that the p38-MK2 kinase pathway is acti-
vated during C. difficile infection and contributes to the host in-
flammatory response in patients with CDI. Phospho-MK2 may be
a useful adjunctive biomarker of disease severity in patients with
CDI, and by blocking toxin-induced cytokine release it may ulti-
mately prove to be a useful adjunctive therapeutic target in C.
difficile-infected patients with severe intestinal inflammation.
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